PRCT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
98.3M
+4.0%
94.5M
+13.7%
83.1M
+8.8%
76.4M
-8.3%
83.3M
Cost of Revenue
33.1M
+3.2%
32.1M
+10.1%
29.2M
-2.9%
30.1M
+2.6%
29.3M
Gross Profit
65.1M
+4.4%
62.4M
+15.6%
53.9M
+16.5%
46.3M
-14.2%
54.0M
Operating Expenses
92.5M
+3.1%
89.8M
+3.7%
86.6M
+11.9%
77.4M
+0.2%
77.2M
R&D
20.0M
-0.4%
20.1M
-6.4%
21.5M
+12.6%
19.1M
+4.8%
18.2M
SG&A
72.5M
+4.1%
69.7M
+7.0%
65.1M
+11.6%
58.3M
-1.2%
59.0M
Operating Income
-27376000
+0.1%
-27390000
+16.0%
-32606000
-5.0%
-31041000
-33.8%
-23192000
EBITDA
-24836000
+2.2%
-25401000
+17.7%
-30871000
-5.2%
-29332000
-36.0%
-21574000
Net Income
-26516000
+1.3%
-26861000
+15.1%
-31638000
-6.0%
-29845000
-39.4%
-21411000
EPS (Basic)
$-0.46
+2.1%
$-0.47
+16.1%
$-0.56
-5.7%
$-0.53
-39.5%
$-0.38
EPS (Diluted)
$-0.46
+2.1%
$-0.47
+16.1%
$-0.56
-5.7%
$-0.53
-39.5%
$-0.38
Shares (Diluted)
57.3M
+0.5%
57.1M
+1.0%
56.5M
+0.8%
56.1M
+0.6%
55.7M
PROCEPT BioRobotics (PRCT) — Financials